http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박정보,김민주,이승수,김중완,전언찬 한국공작기계학회 2004 한국생산제조학회지 Vol.13 No.5
In this study, we have developed the simulation tool in order to investigate driving trajectory of AGV for container transport. AGV for container transport is different from the indoor AGV in that it is a large size structure at being loaded the weight of 40 ton. And AGV for container transport is applied to front wheel steering, rear wheel steering, all wheel steering, and crap steering. Therefore, we have developed the simulation tool considering dynamic problems and a center of turning in accordance with fourth ways of steering mode. As the result of this study, we have confirmed that this tool is useful and cost-effective in the dynamic analysis or large size vehicles. Also, it is useful to calculate the minimum radius of turning for large size vehicles.
Kim, Yeon-Joo,Lee, Woo Jin,Woo, Sang Myung,Kim, Tae Hyun,Han, Sung-Sik,Kim, Bo Hyun,Moon, Sung Ho,Kim, Sang Soo,Koh, Young Hwan,Park, Sang-Jae,Kim, Joo-Young,Kim, Dae Yong,Park, Joong-Won BioMed Central 2013 Radiation oncology Vol.8 No.-
<P><B>Background</B></P><P>Although capecitabine has theoretical advantages in the pharmacokinetics, such as higher intratumoral and lower systemic concentration, relative to bolus 5-fluorouracil (5-FU), outcomes of chemoradiotherapy (CRT) with capecitabine or bolus 5-FU have not been directly compared in patients with locally advanced pancreatic cancer. Therefore, we retrospectively compared the outcomes, including toxicity, tumor response, and overall survival, of oral capecitabine plus radiotherapy (RT) with bolus 5-FU plus RT, in patients with locally advanced pancreatic cancer.</P><P><B>Methods</B></P><P>Between August 2006 and January 2012, 98 patients with locally advanced pancreatic cancer received CRT, with 52 receiving concurrent oral capecitabine and 46 receiving bolus injection of 5-FU. Primary tumor and overall response after CRT were evaluated radiologically, and toxicity, tumor response, and overall survival (OS) were compared in the two groups.</P><P><B>Results</B></P><P>Baseline clinical parameters of the two groups were similar. The rates of ≥ Grade 3 hematologic (0% vs. 8.7%, <I>p</I> = 0.045) and non-hematologic (0% vs. 8.7%, <I>p</I> = 0.045) toxicities were significantly lower in the capecitabine group than in the 5-FU group. Primary tumor (30.7% vs. 28.2%, <I>p</I> = 0.658) and overall (13.7% vs. 15.2%, <I>p</I> = 0.273) response rates and median OS time (12.5 months vs. 11.6 months, <I>p</I> = 0.655) were similar in the two groups.</P><P><B>Conclusions</B></P><P>Capecitabine plus RT may be a safe and feasible regimen for patients with locally advanced pancreatic cancer, with similar efficacy and low rates of toxicities compared with bolus 5-FU plus RT.</P>
Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma
Kim, Tae Hyun,Park, Joong-Won,Kim, Yeon-Joo,Kim, Bo Hyun,Woo, Sang Myung,Moon, Sung Ho,Kim, Sang Soo,Koh, Young-Hwan,Lee, Woo Jin,Park, Sang Jae,Kim, Joo-Young,Kim, Dae Yong,Kim, Chang-Min Korean Cancer Association 2015 Cancer Research and Treatment Vol.47 No.1
<P><B>Purpose</B></P><P>The purpose of this study is to determine the optimal dose of proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients.</P><P><B>Materials and Methods</B></P><P>Inoperable HCC patients who had naïve, recurrent, or residual tumor to treatment were considered eligible for PBT. Patients received PBT with 60 GyE in 20 fractions (dose level 1; equivalent dose in 2 Gy fractions [EQD2], 65 GyE<SUB>10</SUB>); 66 GyE in 22 fractions (dose level 2; EQD2, 71.5 GyE<SUB>10</SUB>); or 72 GyE in 24 fractions (dose level 3; EQD2, 78 GyE<SUB>10</SUB>). Dose-limiting toxicity was determined by grade ≥ 3 acute toxicity.</P><P><B>Results</B></P><P>Twenty-seven patients were enrolled; eight, seven, and 12 patients were treated with dose levels 1, 2, and 3, respectively. Overall, treatment was well tolerated, with no dose-limiting toxicities. The complete response (CR) rates of primary tumors after PBT for dose levels 1, 2, and 3 were 62.5% (5/8), 57.1% (4/7), and 100% (12/12), respectively (p=0.039). The 3-and 5-year local progression-free survival (LPFS) rates among 26 patients, excluding one patient who underwent liver transplantation after PBT due to its probable significant effect on disease control, were 79.9% and 63.9%, respectively, and the 3-and 5-year overall survival rates were 56.4% and 42.3%, respectively. The 3-year LPFS rate was significantly higher in patients who achieved CR than in those who did not (90% vs. 40%, p=0.003).</P><P><B>Conclusion</B></P><P>PBT is safe and effective and an EQD2 ≥ 78 GyE<SUB>10</SUB> should be delivered for achievement of local tumor control.</P>
( Young Il Kim ),( Joong Won Park ),( Hee Won Kwak ),( Bo Hyun Kim ),( Tae Hyun Kim ),( Seong Hoon Kim ),( Young Hwan Koh ),( Hyun Beom Kim ),( Chang Min Kim ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: All of outcome studies for hepatocellular carcinoma (HCC) treatments have been based on initial treatments. However, in most patients with HCC, recurrence or progression after initial treatment frequently occurs, and succeeding treatments are necessary for control of disease. In this study, we analyzed the clinical outcomes of patients with HCC based on the second treatment. Methods: A cohort of 1,972 patients newly diagnosed with HCC and treated at the National Cancer Center, Korea between January 2004 and December 2009 was used for this study. After exclusion of supportive care cases, 1,687 patients were studied for progression-free survival (PFS), recorded second treatments after progression, and overall survival (OS) after the second treatment. Results: Median age of patients was 57 years. OS of these patients was 26.9 months. Among 1,687 patients, 1,359 patients (80.6%) had disease progression after initial treatments. Initial treatment was resection (21.6%), transplantation (1.8%), locoregional treatments including radiofrequency ablation or percutaneous ethanol injection therapy (4.5%), transarterial chemoembolization (TACE) (64.6%), external radiotherapy (RT) (3.2%), or systemic chemotherapy (4.3%). Median PFS was 21.2 months. In these patients with progression, resection (2.3%), transplantation (1.3%), locoregional treatments (5.0%), TACE (51.6%), RT (3.7%), systemic chemotherapy (12.5%), or supportive care only (22.7%) was performed as the second treatment. Median OS after the second treatment was 15.6 months. According to each second treatment, median OS were 35.0 months in resection, 47.5 months in locoregional treatments, 17.9 months in TACE, 19.1 months in RT, 7.9 months in systemic chemotherapy, and 9.7 months in supportive care, respectively (P< 0.001, log-rank test). Further outcome analysis in each second treatment will be presented. Conclusions: This observational study provides insights into HCC disease characteristics and clinical outcomes after the first and the second treatments for the first time and may be useful in future research of HCC treatment strategies.
Rapid generation of OPC-like cells from human pluripotent stem cells for treating spinal cord injury
Kim, Dae-Sung,Jung, Se Jung,Lee, Jae Souk,Lim, Bo Young,Kim, Hyun Ah,Yoo, Jeong-Eun,Kim, Dong-Wook,Leem, Joong Woo Nature Publishing Group 2017 Experimental and molecular medicine Vol.49 No.7
<P>Remyelination via the transplantation of oligodendrocyte precursor cells (OPCs) has been considered as a strategy to improve the locomotor deficits caused by traumatic spinal cord injury (SCI). To date, enormous efforts have been made to derive OPCs from human pluripotent stem cells (hPSCs), and significant progress in the transplantation of such cells in SCI animal models has been reported. The current methods generally require a long period of time (>2 months) to obtain transplantable OPCs, which hampers their clinical utility for patients with SCI. Here we demonstrate a rapid and efficient method to differentiate hPSCs into neural progenitors that retain the features of OPCs (referred to as OPC-like cells). We used cell sorting to select A2B5-positive cells from hPSC-derived neural rosettes and cultured the selected cells in the presence of signaling cues, including sonic hedgehog, PDGF and insulin-like growth factor-1. This method robustly generated neural cells positive for platelet-derived growth factor receptor-α (PDGFRα) and NG2 (~90%) after 4 weeks of differentiation. Behavioral tests revealed that the transplantation of the OPC-like cells into the spinal cords of rats with contusive SCI at the thoracic level significantly improved hindlimb locomotor function. Electrophysiological assessment revealed enhanced neural conduction through the injury site. Histological examination showed increased numbers of axon with myelination at the injury site and graft-derived myelin formation with no evidence of tumor formation. Our method provides a cell source from hPSCs that has the potential to recover motor function following SCI.</P>
( Bo Young Lee ),( Joong-won Park ),( Bo Hyun Kim ),( Minjong Lee ),( Ju Hee Lee ),( Young Hwan Koh ),( Eun Kyung Hong ),( Chang-min Kim ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Sorafenib has been the only approved systemic agent for advanced hepatocellular carcinoma (HCC). A recent meta-analysis suggested that sorafenib benefit may depend on viral status and was observed only in hepatitis B virus (HBV)-negative and hepatitis C virus (HCV)-positive patients. The aim of this study is to investigate sorafenib response between HBV and non-HBV patients with HCC in real-world practice. Methods: From June 2007 to March 2018, 703 patients with unresectable HCC who had been treated with sorafenib for more than 4 weeks in the National Cancer Center, Korea were enrolled. Patient demographics and overall survival (OS) were compared between HBV-related HCC and non-HBV-related HCC. Results: Among 703 patients, 518 (73.7%) were HBV-related and 185 (26.3%) were non-HBV-related (HCV, 8.0%; alcoholic, 8.4%; others, 9.9%). The HBV-related group was younger (median age, 54.5 vs. 66; P=0.210). The majority of both group had good liver function (Child-Pugh class A, 92.3% vs. 94.6%; P=0.293) and performance status (ECOG score of 0, 64.0% vs.65.8%; P=0.667). In HBV-related group, 33.6% and 48.3% were modified UICC stage IVa and IVb, respectively, while 33.5% and 43.8% of non-HBV-related group were modified UICC stage IVa and IVb, respectively. The median duration of sorafenib treatment was 2.9 months in HBV-related group (range, 0.9 - 73.0 months) and 3.7 months in non-HBV-related group (range, 0.9 - 72.8 months). The median OS of HBV-related and non-HBV-related group was 8.7 months (95% confidence interval [CI], 7.7 - 9.6) and 11.0 months (95% CI,9.3 -12.6); however, it was not statistically significant (P=0.292). Multivariable analysis indicated that prior history of anti-tumor therapy, Child-Pugh class B, presence of portal vein invasion, and alpha-fetoprotein level ≥ 100ng/ml were independent predictors for OS in patients treated with sorafenib; however, etiology of HCC failed to show the impact on OS. Conclusions: In comparison to non-HBV status, the HBV infection status did not affect the outcomes of sorafenib treatment in patients with advanced HCC in an HBV endemic area.